In the early settlement mechanism for drug patent disputes the holder of the drug marketing authorization is obliged to ensurethe completeness and accuracy of the registered drug patent information. If the holder of the drug marketing authorization abusesthe procedure of drug patent information registration in a dominant market position it may constitute the violation of antitrsut law andneeds to be regulated by antitrsut laws. The specialized agency for antitrsut law enforcement can regulate the registration of drug patentinformation and the generic pharmaceutical company can initiate antitrust civil litigation to exclude or correct erroneous patent information.The subjective intention of the pharmaceutical patent holder can be an constitutive elements of an abuse of monopoly statusand it is necessary to prevent the improper expansion of the scope of the patent right for drug patent information registration. The holderof the drug marketing authorization shall bear legal responsibility for modifying or deleting the erroneously registered drug patent informationas well as for compensating damages to the generic pharmaceutical company.